|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
2
|
Reungwetwattana T, Weroha SJ and Molina
JR: Oncogenic pathways, molecularly targeted therapies, and
highlighted clinical trials in non-small-cell lung cancer (NSCLC).
Clin Lung Cancer. 13:252–266. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schiller JH: Small cell lung cancer:
defining a role for emerging platinum drugs. Oncology. 63:105–114.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Roy M, Luo YH, Ye M and Liu J: Nonsmall
cell lung cancer therapy: insight into multitargeted small-molecule
growth factor receptor inhibitors. Biomed Res Int.
2013:9647432013.PubMed/NCBI
|
|
5
|
Medzhitov R, Preston-Hurlburt P and
Janeway CA Jr: A human homologue of the Drosophila Toll
protein signals activation of adaptive immunity. Nature.
388:394–397. 1997. View
Article : Google Scholar
|
|
6
|
Takeda K, Kaisho T and Akira S: Toll-like
receptors. Annu Rev Immunol. 21:335–376. 2003. View Article : Google Scholar
|
|
7
|
Medzhitov R and Janeway CA Jr: Decoding
the patterns of self and nonself by the innate immune system.
Science. 296:298–300. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Elson G, Dunn-Siegrist I, Daubeuf B and
Pugin J: Contribution of Toll-like receptors to the innate immune
response to Gram-negative and Gram-positive bacteria. Blood.
109:1574–1583. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
De Bouteiller O, Merck E, Hasan UA, et al:
Recognition of double-stranded RNA by human toll-like receptor 3
and downstream receptor signaling requires multimerization and an
acidic pH. J Biol Chem. 280:38133–38145. 2005.PubMed/NCBI
|
|
10
|
Goto Y, Arigami T, Kitago M, et al:
Activation of Toll-like receptors 2, 3, and 4 on human melanoma
cells induces inflammatory factors. Mol Cancer Ther. 7:3642–3653.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kelly MG, Alvero AB, Chen R, et al: TLR-4
signaling promotes tumor growth and paclitaxel chemoresistance in
ovarian cancer. Cancer Res. 66:3859–3868. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fukata M, Chen A, Vamadevan AS, et al:
Toll-like receptor-4 promotes the development of colitis-associated
colorectal tumors. Gastroenterology. 133:1869–1881. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
O’Neill LA, Bryant CE and Doyle SL:
Therapeutic targeting of Toll-like receptors for infectious and
inflammatory diseases and cancer. Pharmacol Rev. 61:177–197.
2009.PubMed/NCBI
|
|
14
|
Yu L and Chen S: Toll-like receptors
expressed in tumor cells: targets for therapy. Cancer Immunol
Immunother. 57:1271–1278. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Garza-Gonzalez E, Bosques-Padilla FJ,
Mendoza-Ibarra SI, Flores-Gutierrez JP, Maldonado-Garza HJ and
Perez-Perez GI: Assessment of the toll-like receptor 4 Asp299Gly,
Thr399Ile and interleukin-8 −251 polymorphisms in the risk for the
development of distal gastric cancer. BMC Cancer.
7:702007.PubMed/NCBI
|
|
16
|
Wang JP, Zhang Y, Wei X, et al:
Circulating Toll-like receptor (TLR) 2, TLR4, and regulatory T
cells in patients with chronic hepatitis C. APMIS. 118:261–270.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang H, Zhou H, Feng P, et al: Reduced
expression of Toll-like receptor 4 inhibits human breast cancer
cells proliferation and inflammatory cytokines secretion. J Exp
Clin Cancer Res. 29:922010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
He W, Liu Q, Wang L, Chen W, Li N and Cao
X: TLR4 signaling promotes immune escape of human lung cancer cells
by inducing immunosuppressive cytokines and apoptosis resistance.
Mol Immunol. 44:2850–2859. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hiratsuka S, Watanabe A, Sakurai Y, et al:
The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a
pre-metastatic phase. Nat Cell Biol. 10:1349–1355. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang YB, He FL, Fang M, et al: Increased
expression of Toll-like receptors 4 and 9 in human lung cancer. Mol
Biol Rep. 36:1475–1481. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
22
|
Campo E, Merino MJ, Liotta L, Neumann R
and Stetler-Stevenson W: Distribution of 72KD type IV collagenase
in nonneoplastic and neoplastic thyroid tissue. Hum Pathol.
23:1395–1401. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lowry OH, Rosebrough NJ, Farr AL and
Randall RJ: Protein measurement with the Folin phenol reagent. J
Biol Chem. 193:265–275. 1951.PubMed/NCBI
|
|
24
|
Zhang D, Chen ZG, Liu SH, et al:
Galectin-3 gene silencing inhibits migration and invasion of human
tongue cancer cells in vitro via downregulating beta-catenin. Acta
Pharmacol Sin. 34:176–184. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mendez M, Custodio A and Provencio M: New
molecular targeted therapies for advanced non-small-cell lung
cancer. J Thorac Dis. 3:30–56. 2011.PubMed/NCBI
|
|
26
|
Yao H and Rahman I: Current concepts on
the role of inflammation in COPD and lung cancer. Curr Opin
Pharmacol. 9:375–383. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bauer AK, Dixon D, DeGraff LM, et al:
Toll-like receptor 4 in butylated hydroxytoluene-induced mouse
pulmonary inflammation and tumorigenesis. J Natl Cancer Inst.
97:1778–1781. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bauer AK, Fostel J, Degraff LM, et al:
Transcriptomic analysis of pathways regulated by toll-like receptor
4 in a murine model of chronic pulmonary inflammation and
carcinogenesis. Mol Cancer. 8:1072009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Szczepanski MJ, Czystowska M, Szajnik M,
et al: Triggering of Toll-like receptor 4 expressed on human head
and neck squamous cell carcinoma promotes tumor development and
protects the tumor from immune attack. Cancer Res. 69:3105–3113.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang B, Zhao J, Li H, et al: Toll-like
receptors on tumor cells facilitate evasion of immune surveillance.
Cancer Res. 65:5009–5014. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hua D, Liu MY, Cheng ZD, et al: Small
interfering RNA-directed targeting of Toll-like receptor 4 inhibits
human prostate cancer cell invasion, survival, and tumorigenicity.
Mol Immunol. 46:2876–2884. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ahmed A, Wang JH and Redmond HP: Silencing
of TLR4 increases tumor progression and lung metastasis in a murine
model of breast cancer. Ann Surg Oncol. 20(Suppl 3): S389–S396.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kusmartsev S and Gabrilovich DI: Immature
myeloid cells and cancer-associated immune suppression. Cancer
Immunol Immunother. 51:293–298. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gatti G, Quintar AA, Andreani V, et al:
Expression of Toll-like receptor 4 in the prostate gland and its
association with the severity of prostate cancer. Prostate.
69:1387–1397. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Starska K, Forma E, Brys M, et al: The
expression of TLR pathway molecules in peripheral blood mononuclear
cells and their relationship with tumor invasion and cytokine
secretion in laryngeal carcinoma. Adv Med Sci. 57:124–135. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hartmann E, Wollenberg B, Rothenfusser S,
et al: Identification and functional analysis of tumor-infiltrating
plasmacytoid dendritic cells in head and neck cancer. Cancer Res.
63:6478–6487. 2003.PubMed/NCBI
|
|
38
|
Oka N, Tanimoto S, Taue R, et al: Role of
phosphatidylinositol-3 kinase/Akt pathway in bladder cancer cell
apoptosis induced by tumor necrosis factor-related
apoptosis-inducing ligand. Cancer Sci. 97:1093–1098. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kai K, D’Costa S, Sills RC and Kim Y:
Inhibition of the insulin-like growth factor 1 receptor pathway
enhances the antitumor effect of cisplatin in human malignant
mesothelioma cell lines. Cancer Lett. 278:49–55. 2009. View Article : Google Scholar : PubMed/NCBI
|
